A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

Abstract Background Novel therapies for patients with acute myeloid leukemia (AML) are imperative, particularly for those with high-risk features. Selinexor, an exportin 1 (XPO1/CRM1) inhibitor, has demonstrated anti-leukemia activity as a single agent, as well as in combination with anthracyclines...

Full description

Bibliographic Details
Main Authors: Amy Y. Wang, Howard Weiner, Margaret Green, Hua Chang, Noreen Fulton, Richard A. Larson, Olatoyosi Odenike, Andrew S. Artz, Michael R. Bishop, Lucy A. Godley, Michael J. Thirman, Satyajit Kosuri, Jane E. Churpek, Emily Curran, Kristen Pettit, Wendy Stock, Hongtao Liu
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Journal of Hematology & Oncology
Subjects:
AML
Selinexor
Induction chemotherapy
XPO1/CRM1
Online Access:http://link.springer.com/article/10.1186/s13045-017-0550-8

Internet

http://link.springer.com/article/10.1186/s13045-017-0550-8

Similar Items